Renal Cell Carcinoma News
Active surveillance appears to be a safe alternative to primary intervention for selected patients with small renal masses.
Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.
Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.
Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.
Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.
Patients with kidney tumors with pathology indicating a fumarate hydratase (FH) mutation should be referred for genetic testing.
ASCO published new recommendations for the management of patients with clinically localized small renal masses (SRMs).
Combining dalantercept with axitinib treatment may improve clinical outcomes for previously treated patients with renal cell carcinoma (RCC).
Adjuvant chemotherapy after radical nephroureterectomy (RNU) may improve overall survival compared with observation alone.
Allosteric inhibition of AKT with MK-2206 is not superior to everolimus for the treatment of patients with advanced renal cell carcinoma (RCC).
Among patients with intermediate- or poor-risk metastatic renal cell carcinoma (mRCC), first-line therapy with cabozantinib was superior to standard-of-care.
Among patients with intermediate-risk metastatic clear cell renal cell carcinoma (ccRCC), nephrectomy after upfront pazopanib therapy is feasible.
Sonepcizumab improves overall survival of patients with metastatic renal cell carcinoma (mRCC).
Adjuvant treatment with sunitinib prolonged disease-free survival, and was associated with a manageable safety profile.
The vaccine IMA901 did not improve overall survival when added to sunitinib as a first-line treatment for patients with metastatic renal cell carcinoma (RCC).
First-line single-agent everolimus provides some clinical benefit to patients with papillary metastatic renal cell carcinoma (mRCC).
The U.S. Food and Drug Administration (FDA) has modified the dosage regimen for nivolumab for the approved indications.
Downregulated FASN gene expression may improve the overall survival of patients with metastatic renal cell carcinoma (RCC).
CTA has updated its treatment regimen chart for the treatment of renal cell carcinoma to reflect NCCN Guidelines for Kidney Cancer.
Interleukin-10 (AM0010) demonstrates antitumor activity, with an acceptable toxicity profile, in patients with renal cell carcinoma (RCC).
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|